IL
Illinois House Bill HB4450

Illinois 2023-2024 Regular Session

Illinois House Bill HB4450 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED: 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance. LRB103 36645 RLC 66754 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED: 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance. LRB103 36645 RLC 66754 b LRB103 36645 RLC 66754 b A BILL FOR
22 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:
33 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
44 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
55 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.
66 LRB103 36645 RLC 66754 b LRB103 36645 RLC 66754 b
77 LRB103 36645 RLC 66754 b
88 A BILL FOR
99 HB4450LRB103 36645 RLC 66754 b HB4450 LRB103 36645 RLC 66754 b
1010 HB4450 LRB103 36645 RLC 66754 b
1111 1 AN ACT concerning criminal law.
1212 2 Be it enacted by the People of the State of Illinois,
1313 3 represented in the General Assembly:
1414 4 Section 5. The Illinois Controlled Substances Act is
1515 5 amended by changing Section 208 as follows:
1616 6 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
1717 7 Sec. 208. (a) The controlled substances listed in this
1818 8 Section are included in Schedule III.
1919 9 (b) Unless specifically excepted or unless listed in
2020 10 another schedule, any material, compound, mixture, or
2121 11 preparation which contains any quantity of the following
2222 12 substances having a stimulant effect on the central nervous
2323 13 system, including its salts, isomers (whether optical
2424 14 position, or geometric), and salts of such isomers whenever
2525 15 the existence of such salts, isomers, and salts of isomers is
2626 16 possible within the specific chemical designation;
2727 17 (1) Those compounds, mixtures, or preparations in
2828 18 dosage unit form containing any stimulant substances
2929 19 listed in Schedule II which compounds, mixtures, or
3030 20 preparations were listed on August 25, 1971, as excepted
3131 21 compounds under Title 21, Code of Federal Regulations,
3232 22 Section 308.32, and any other drug of the quantitative
3333 23 composition shown in that list for those drugs or which is
3434
3535
3636
3737 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:
3838 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
3939 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
4040 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.
4141 LRB103 36645 RLC 66754 b LRB103 36645 RLC 66754 b
4242 LRB103 36645 RLC 66754 b
4343 A BILL FOR
4444
4545
4646
4747
4848
4949 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
5050
5151
5252
5353 LRB103 36645 RLC 66754 b
5454
5555
5656
5757
5858
5959
6060
6161
6262
6363 HB4450 LRB103 36645 RLC 66754 b
6464
6565
6666 HB4450- 2 -LRB103 36645 RLC 66754 b HB4450 - 2 - LRB103 36645 RLC 66754 b
6767 HB4450 - 2 - LRB103 36645 RLC 66754 b
6868 1 the same except that it contains a lesser quantity of
6969 2 controlled substances;
7070 3 (2) Benzphetamine;
7171 4 (3) Chlorphentermine;
7272 5 (4) Clortermine;
7373 6 (5) Phendimetrazine.
7474 7 (c) Unless specifically excepted or unless listed in
7575 8 another schedule, any material, compound, mixture, or
7676 9 preparation which contains any quantity of the following
7777 10 substances having a potential for abuse associated with a
7878 11 depressant effect on the central nervous system:
7979 12 (1) Any compound, mixture, or preparation containing
8080 13 amobarbital, secobarbital, pentobarbital or any salt
8181 14 thereof and one or more other active medicinal ingredients
8282 15 which are not listed in any schedule;
8383 16 (2) Any suppository dosage form containing
8484 17 amobarbital, secobarbital, pentobarbital or any salt of
8585 18 any of these drugs and approved by the Federal Food and
8686 19 Drug Administration for marketing only as a suppository;
8787 20 (3) Any substance which contains any quantity of a
8888 21 derivative of barbituric acid, or any salt thereof:
8989 22 (3.1) Aprobarbital;
9090 23 (3.2) Butabarbital (secbutabarbital);
9191 24 (3.3) Butalbital;
9292 25 (3.4) Butobarbital (butethal);
9393 26 (4) Chlorhexadol;
9494
9595
9696
9797
9898
9999 HB4450 - 2 - LRB103 36645 RLC 66754 b
100100
101101
102102 HB4450- 3 -LRB103 36645 RLC 66754 b HB4450 - 3 - LRB103 36645 RLC 66754 b
103103 HB4450 - 3 - LRB103 36645 RLC 66754 b
104104 1 (5) Methyprylon;
105105 2 (6) Sulfondiethylmethane;
106106 3 (7) Sulfonethylmethane;
107107 4 (8) Sulfonmethane;
108108 5 (9) Lysergic acid;
109109 6 (10) Lysergic acid amide;
110110 7 (10.1) Tiletamine or zolazepam or both, or any salt of
111111 8 either of them.
112112 9 Some trade or other names for a tiletamine-zolazepam
113113 10 combination product: Telazol.
114114 11 Some trade or other names for Tiletamine:
115115 12 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
116116 13 Some trade or other names for zolazepam:
117117 14 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
118118 15 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
119119 16 (11) Any material, compound, mixture or preparation
120120 17 containing not more than 12.5 milligrams of pentazocine or
121121 18 any of its salts, per 325 milligrams of aspirin;
122122 19 (12) Any material, compound, mixture or preparation
123123 20 containing not more than 12.5 milligrams of pentazocine or
124124 21 any of its salts, per 325 milligrams of acetaminophen;
125125 22 (13) Any material, compound, mixture or preparation
126126 23 containing not more than 50 milligrams of pentazocine or
127127 24 any of its salts plus naloxone HCl USP 0.5 milligrams, per
128128 25 dosage unit;
129129 26 (14) Ketamine;
130130
131131
132132
133133
134134
135135 HB4450 - 3 - LRB103 36645 RLC 66754 b
136136
137137
138138 HB4450- 4 -LRB103 36645 RLC 66754 b HB4450 - 4 - LRB103 36645 RLC 66754 b
139139 HB4450 - 4 - LRB103 36645 RLC 66754 b
140140 1 (15) Thiopental; .
141141 2 (16) Xylazine: (N-2,6-dimethylpheny1)-5,6-
142142 3 dihydro-4H-1,3 thiazin-2-amine), including its isomers,
143143 4 esters, ethers, salts, and salts of isomers, esters, and
144144 5 ethers, whenever the existence of such isomers, esters,
145145 6 ethers, and salts is possible within the specific chemical
146146 7 designation.
147147 8 (d) Nalorphine.
148148 9 (d.5) Buprenorphine.
149149 10 (e) Unless specifically excepted or unless listed in
150150 11 another schedule, any material, compound, mixture, or
151151 12 preparation containing limited quantities of any of the
152152 13 following narcotic drugs, or their salts calculated as the
153153 14 free anhydrous base or alkaloid, as set forth below:
154154 15 (1) not more than 1.8 grams of codeine per 100
155155 16 milliliters or not more than 90 milligrams per dosage
156156 17 unit, with an equal or greater quantity of an isoquinoline
157157 18 alkaloid of opium;
158158 19 (2) not more than 1.8 grams of codeine per 100
159159 20 milliliters or not more than 90 milligrams per dosage
160160 21 unit, with one or more active non-narcotic ingredients in
161161 22 recognized therapeutic amounts;
162162 23 (3) (blank);
163163 24 (4) (blank);
164164 25 (5) not more than 1.8 grams of dihydrocodeine per 100
165165 26 milliliters or not more than 90 milligrams per dosage
166166
167167
168168
169169
170170
171171 HB4450 - 4 - LRB103 36645 RLC 66754 b
172172
173173
174174 HB4450- 5 -LRB103 36645 RLC 66754 b HB4450 - 5 - LRB103 36645 RLC 66754 b
175175 HB4450 - 5 - LRB103 36645 RLC 66754 b
176176 1 unit, with one or more active, non-narcotic ingredients in
177177 2 recognized therapeutic amounts;
178178 3 (6) not more than 300 milligrams of ethylmorphine per
179179 4 100 milliliters or not more than 15 milligrams per dosage
180180 5 unit, with one or more active, non-narcotic ingredients in
181181 6 recognized therapeutic amounts;
182182 7 (7) not more than 500 milligrams of opium per 100
183183 8 milliliters or per 100 grams, or not more than 25
184184 9 milligrams per dosage unit, with one or more active,
185185 10 non-narcotic ingredients in recognized therapeutic
186186 11 amounts;
187187 12 (8) not more than 50 milligrams of morphine per 100
188188 13 milliliters or per 100 grams with one or more active,
189189 14 non-narcotic ingredients in recognized therapeutic
190190 15 amounts.
191191 16 (f) Anabolic steroids, except the following anabolic
192192 17 steroids that are exempt:
193193 18 (1) Androgyn L.A.;
194194 19 (2) Andro-Estro 90-4;
195195 20 (3) depANDROGYN;
196196 21 (4) DEPO-T.E.;
197197 22 (5) depTESTROGEN;
198198 23 (6) Duomone;
199199 24 (7) DURATESTRIN;
200200 25 (8) DUO-SPAN II;
201201 26 (9) Estratest;
202202
203203
204204
205205
206206
207207 HB4450 - 5 - LRB103 36645 RLC 66754 b
208208
209209
210210 HB4450- 6 -LRB103 36645 RLC 66754 b HB4450 - 6 - LRB103 36645 RLC 66754 b
211211 HB4450 - 6 - LRB103 36645 RLC 66754 b
212212 1 (10) Estratest H.S.;
213213 2 (11) PAN ESTRA TEST;
214214 3 (12) Premarin with Methyltestosterone;
215215 4 (13) TEST-ESTRO Cypionates;
216216 5 (14) Testosterone Cyp 50 Estradiol Cyp 2;
217217 6 (15) Testosterone Cypionate-Estradiol Cypionate
218218 7 injection; and
219219 8 (16) Testosterone Enanthate-Estradiol Valerate
220220 9 injection.
221221 10 (g) Hallucinogenic substances.
222222 11 (1) Dronabinol (synthetic) in sesame oil and
223223 12 encapsulated in a soft gelatin capsule in a U.S. Food and
224224 13 Drug Administration approved product. Some other names for
225225 14 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
226226 15 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
227227 16 (-)-delta-9-(trans)-tetrahydrocannabinol.
228228 17 (2) (Reserved).
229229 18 (h) The Department may except by rule any compound,
230230 19 mixture, or preparation containing any stimulant or depressant
231231 20 substance listed in subsection (b) from the application of all
232232 21 or any part of this Act if the compound, mixture, or
233233 22 preparation contains one or more active medicinal ingredients
234234 23 not having a stimulant or depressant effect on the central
235235 24 nervous system, and if the admixtures are included therein in
236236 25 combinations, quantity, proportion, or concentration that
237237 26 vitiate the potential for abuse of the substances which have a
238238
239239
240240
241241
242242
243243 HB4450 - 6 - LRB103 36645 RLC 66754 b
244244
245245
246246 HB4450- 7 -LRB103 36645 RLC 66754 b HB4450 - 7 - LRB103 36645 RLC 66754 b
247247 HB4450 - 7 - LRB103 36645 RLC 66754 b
248248
249249
250250
251251
252252
253253 HB4450 - 7 - LRB103 36645 RLC 66754 b